Artificial intelligence is working its way into two very different corners of the drug industry at once: the unglamorous science of formulation, and the high-stakes business of discovering new medicines.
According to a GlobeNewswire release carried by Yahoo Finance, market research firm BCC Research says AI is disrupting topical drug delivery — the creams, gels and patches that deliver medicine through the skin. The release points to billion-dollar partnerships and $3.3 billion in venture capital funding as evidence of what it calls a structural shift in pharmaceutical formulation. BCC Research projects the global topical drug delivery market will reach $362.3 billion by 2031, and highlights AI's role in personalized therapy and permeability modeling — essentially, predicting how well a compound will actually cross the skin barrier.
Meanwhile, the industry's largest players are moving. Endpoints News reports that the biggest names behind biotech stocks are investing richly in artificial intelligence, with the goal of speeding up drug development. That framing matters: these are not startups betting the company on a new tool, but incumbents treating AI as a new competitive arena.
Regulators and compliance teams are adjusting too. A conference listing promoted through Yahoo Finance, "FDA Inspection Readiness in the AI Era 2026," scheduled for August 20–21, 2026, pitches AI-enabled continuous inspection readiness, stronger GMP and data-integrity compliance, and more effective CAPA and quality-culture systems — a sign that the AI conversation in pharma has spread from labs into quality and audit functions.
A caveat worth keeping: much of the topical-delivery framing comes from a market research firm's own promotional release, not independent reporting.
Why it matters: if AI genuinely shortens the path from molecule to medicine — and makes formulations more precisely tailored to individual patients — the payoff shows up as drugs that arrive sooner and work better for more people.